1959
DOI: 10.1001/archinte.1959.00270050105016
|View full text |Cite
|
Sign up to set email alerts
|

Reduction of Serum Cholesterol Levels and Beta-Lipoprotein Cholesterol Levels by Nicotinic Acid

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
17
0
1

Year Published

1960
1960
2015
2015

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 88 publications
(18 citation statements)
references
References 11 publications
0
17
0
1
Order By: Relevance
“…On the other hand, there are some patients in whom the total sterol level drops significantly, and the mean drop is in the neighborhood of 15 per cent. This degree of response compares unfavorably with the therapeutic responses that have been obtained using dietary treatment with unsaturated fat, or low fat diets, or with nicotinic acid (30)(31)(32).…”
Section: Discussionmentioning
confidence: 85%
“…On the other hand, there are some patients in whom the total sterol level drops significantly, and the mean drop is in the neighborhood of 15 per cent. This degree of response compares unfavorably with the therapeutic responses that have been obtained using dietary treatment with unsaturated fat, or low fat diets, or with nicotinic acid (30)(31)(32).…”
Section: Discussionmentioning
confidence: 85%
“…Perhaps the strongest evidence for a role of stratum corneum lipids in the modulation of stratum corneum desquamation derives from the observation that a number of scaling disorders occur in acquired or inherited defects of lipid metabolism. Ichthyosis, palmarplantar keratoderma, and acanthosis nigricans, occur as side effects of several drugs (26)(27)(28)(29) that interfere with cholesterol biosynthesis or lower serum cholesterol by as yet unknown mechanisms. As reported here, RXLI scales contain not only increased cholesterol sulfate, but also decreased free sterols, raising the possibility that the reduction of free sterols may also regulate desquamation in RXLI.…”
Section: Resultsmentioning
confidence: 99%
“…Since Altschul et al discovered nicotinic acid (niacin) lowered plasma cholesterol (Altschul et al 1955;Parsons Jr and Flinn 1959), it has been used as a broad-spectrum antiatherosclerosis agent for over 50 years because of its beneficial effects on lipid profiles in human (Carlson 2005), lowering levels of very-low-density lipoprotein (LDL), LDL, and triglycerides, while raising levels of high-density lipoprotein cholesterol (Benyo et al 2005;Hanson et al 2010;Eaton et al 1969;Ganji et al 2004;Le Goff et al 2004). However, its clinical use to patient is limited by the severe side effects of cutaneous vasodilation called flushing (Benyo et al 2005;Hanson et al 2010).…”
Section: Introductionmentioning
confidence: 99%